AI Article Synopsis

  • The AZURE study was a 76-week clinical trial comparing two treatment regimens of aflibercept in patients with neovascular age-related macular degeneration, evaluating a flexible treat-and-extend approach versus a fixed dosing schedule.
  • Patients aged 51 and older who had been on aflibercept for at least a year were randomly assigned to receive either a treat-and-extend regimen or fixed dosing every 8 weeks, with changes monitored based on visual acuity and anatomical results.
  • Results showed that both regimens produced similar changes in best-corrected visual acuity, with high rates of vision maintenance, and the treat-and-extend approach allowed for longer intervals between treatments for some patients without any new safety concerns.

Article Abstract

Introduction: AZURE was a 76-week, randomized, open-label, parallel-group, phase IIIb noninferiority study comparing the efficacy and safety of intravitreal aflibercept (IVT-AFL) in a treat-and-extend (T&E) regimen with fixed dosing in patients with neovascular age-related macular degeneration (nAMD) previously receiving IVT-AFL for ≥ 1 year.

Methods: Patients were aged ≥ 51 years and had completed ≥ 1 year of IVT-AFL treatment prior to enrollment (IVT-AFL once per month [- 1 or + 2 weeks] for 3 months followed by IVT-AFL every 2 months [6-12 weeks]). Patients were randomly assigned (1:1) to receive IVT-AFL 2 mg in either a T&E (minimum treatment interval of 8 weeks with no upper limit, adjusted according to functional and anatomic outcomes, as assessed by the investigator; n = 168), or a fixed dosing regimen (treatment every 8 weeks [± 3 days]; n = 168). The primary endpoint was best-corrected visual acuity (BCVA) change from baseline to week (W) 52. The key secondary endpoint was the proportion of patients maintaining vision (< 15-letter loss) at W52.

Results: The full analysis set comprised 332 patients (T&E: n = 165; fixed dosing: n = 167). Mean BCVA change (baseline to W52) was - 0.3 ± 7.5 vs. - 0.5 ± 8.4 letters (T&E vs. fixed dosing; least-squares mean difference [95% CI]: 0.22 [- 1.51 to 1.96] letters; P < 0.0001 for noninferiority test [5-letter margin]). From baseline to W52, 95.2% (T&E) and 94.0% (fixed dosing) of patients maintained vision. Mean central subfield thickness change from baseline to W52 was - 24 ± 55 (T&E) and - 33 ± 47 (fixed dosing) µm. Last treatment interval to W76 was ≥ 12 weeks for 37.0% of T&E patients. No new safety signals were identified.

Conclusion: IVT-AFL T&E can achieve similar functional and anatomic outcomes to fixed dosing every 8 weeks over 52 weeks in patients with nAMD who have completed ≥ 1 year of treatment, while reducing treatment burden.

Trial Registration: ClinicalTrials.gov Identifier: NCT02540954.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10879225PMC
http://dx.doi.org/10.1007/s12325-023-02719-3DOI Listing

Publication Analysis

Top Keywords

fixed dosing
12
intravitreal aflibercept
8
neovascular age-related
8
age-related macular
8
macular degeneration
8
ivt-afl
6
aflibercept neovascular
4
degeneration year
4
treatment
4
year treatment
4

Similar Publications

Impact of non-weight-dependent low-dose somatropin on bone accrual in childhood-onset GH deficient in the transition: an 18-month randomized controlled trial.

J Pediatr (Rio J)

December 2024

Faculdade de Medicina da Universidade de São Paulo (FMUSP), Instituto da Criança, Unidade de Endocrinologia Pediátrica, São Paulo, São Paulo, Brazil.

Objective: Discontinuation of growth hormone therapy (rhGH) upon completion of linear growth may adversely affect bone mineral density and content (BMD/BMC) in adolescents with childhood-onset GH deficiency (CO-GHD) and predisposition to osteoporosis. Although the benefits of weight-dependent somatropin high doses over bone gain are established, little is known about fixed low doses. We analyzed the impact of non-weight-based low-dose somatropin on bone accrual during the transition among CO-DGH patients, treated since childhood.

View Article and Find Full Text PDF

In recent years, many population pharmacokinetic (popPK) models have been developed for echinocandins to better understand the pharmacokinetics (PK) of these antifungals. This comprehensive review aimed to summarize popPK models of echinocandins (micafungin, caspofungin, anidulafungin, and rezafungin), by focusing on dosage optimization to maximize the probability of attaining the PK/PD target proposed in special populations. A search in PubMed, Embase, Web of Science, and Scopus, supplemented by the bibliography of relevant articles, was conducted from inception to March 2024, including both observational and prospective trials.

View Article and Find Full Text PDF

Purpose: The pharmacokinetic (PK) profile of direct-acting antivirals, namely ledipasvir/sofosbuvir (LDV/SOF), might be altered in patients with acute lymphoblastic leukemia (ALL), affecting the optimum dose needed for hepatitis C virus treatment. Limited data are available evaluating the population PK of LDV/SOF and SOF metabolite GS-331007. We aimed to study whether ALL could affect population PK parameters of LDV, SOF, and the SOF major metabolite GS-331007 in hepatitis C virus-infected children, develop and validate a predictive PK model of LDV/SOF disposition in this special population, and identify their explained and unexplained sources of variability.

View Article and Find Full Text PDF

The objective of this study was to investigate the effect of combining different doses of 3-nitrooxypropanol (3-NOP) with varying forage composition on gas emission and production performance of dairy cows. Seventy-two lactating Danish Holstein cows (36 primiparous and 36 multiparous) were enrolled in a continuous randomized block design with an initial 2-week covariate period followed by application of treatments for 12 consecutive weeks. Initial DMI and ECM yield were 23.

View Article and Find Full Text PDF

The aim of this study was to analyse the effect of breathing parameters, age, gender and disease status on the lung doses of the two ICS+LABA fixed combination dry powder drugs. Breathing parameters of 113 COPD patients were measured while inhaling through emptied NEXThaler® and Ellipta® inhalers and the corresponding lung doses were calculated. Lung dose of Foster® NEXThaler® was superior to the lung dose of Relvar® Ellipta® in around 85% of the patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!